David W. Denning
Keine laufenden Positionen mehr
Karriereverlauf von David W. Denning
Ehemalige bekannte Positionen von David W. Denning
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Stanford University | Corporate Officer/Principal | 01.01.1987 | 01.01.1990 |
| The University of Manchester | Corporate Officer/Principal | 01.01.1990 | - |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | 01.01.1998 | - |
| Gründer | 01.01.1998 | - | |
Myconostica Ltd.
 Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | 14.09.2009 | - |
| Vorsitzender | - | 14.09.2009 | |
| Technik-/Wissenschafts-/F&E-Leiter | 14.09.2009 | - | |
| Gründer | 14.09.2009 | - |
Statistik
International
| Vereinigtes Königreich | 3 |
| Vereinigte Staaten | 2 |
| Israel | 2 |
Operativ
| Director/Board Member | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sektoral
| Consumer Services | 3 |
| Electronic Technology | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Myconostica Ltd.
Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Electronic Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Börse
- Insiders
- David W. Denning
- Erfahrung